NFE2L2 and B-cell chronic lymphocytic leukemia: As to venetoclax, it cannot be ruled out that, as already demonstrated for other leukemias, it can promote dissociation of the Nrf2/Keap-1 complex and target Nrf2 to ubiquitination and proteasomal degradation [173], which would contribute to thwarting antioxidant defenses of CLL cells.